mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2021-12-3-32-35mvjr-1390Research ArticleОБЗОРЫREVIEWПрименение атипичных антипсихотиков в терапии депрессивных эпизодов при биполярном расстройствеThe use of atypical antipsychotics in the therapy of depressive episodes in patients with bipolar disorderhttps://orcid.org/0000-0002-5129-0402СтрельцовЕ. А.Strel’tsovE. A.

Стрельцов Евгений Александрович, кафедра неврологии, нейрохирургии, психиатрии и реабилитологии

Караганда

Evgeny A. Strel’tsov, resident doctor of neurology, neurosurgery, psychiatry and rehabilitology department

Karaganda

lidigi@mail.ruМедицинский Университет КарагандыКазахстанKaraganda Medical UniversityKazakhstan2021300920211233235Copyright © Стрельцов Е.А., 20212021Стрельцов Е.А.Strel’tsov E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/1390

В настоящем обзоре литературы рассмотрены вопросы эффективности и безопасности применения атипичных антипсихотиков при биполярной депрессии. Подробно освещены результаты рандомизированных исследований и систематических метаанализов последних лет. Рассмотрена эффективность приёма препаратов по следующим ключевым точкам исследований: шкалы общего клинического впечатления тяжести состояния (CGI-S), шкалы оценки депрессии Монтгомери-Асберга (MADRS). Системный поиск литературы проводился по базам данных Scopus, Web of Science, MedLine, elibrary и др.

This literature review addresses the effi cacy and safety of atypical antipsychotics in patients with bipolar depression. Th e results of randomized studies and systematic meta-analyses of recent years were revised in detail. The effi cacy of the drug intake was reviewed for the following key research points: Clinical General Impression of Condition Severity Scale (CGI-S) and Montgomery-Asberg Depression Rating Scale (MADRS). A systematic literature search was carried out using Scopus, Web of Science, MedLine, elibrary, and other databases.

биполярное расстройстводепрессивный эпизодатипичные антипсихотикилуразидонкари- празинобзорReferencesTondo L, Vázquez GH, Baldessarini RJ. Depression and Mania in Bipolar Disorder. Curr Neuropharmacol. 2017;15(3):353-358. DOI: 10.2174/1570159X14666160606210811Tondo L, Vázquez GH, Baldessarini RJ. Depression and Mania in Bipolar Disorder. Curr Neuropharmacol. 2017;15(3):353-358. DOI: 10.2174/1570159X14666160606210811Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672-82. DOI: 10.1016/S0140-6736(13)60857-0Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672-82. DOI: 10.1016/S0140-6736(13)60857-0Zargar F, Haghshenas N, Rajabi F, Tarrahi MJ. Eff ectiveness of Dialectical Behavioral Th erapy on Executive Function, Emotional Control and Severity of Symptoms in Patients with Bipolar I Disorder. Adv Biomed Res. 2019;8:59. DOI: 10.4103/abr.abr_42_19Zargar F, Haghshenas N, Rajabi F, Tarrahi MJ. Eff ectiveness of Dialectical Behavioral Th erapy on Executive Function, Emotional Control and Severity of Symptoms in Patients with Bipolar I Disorder. Adv Biomed Res. 2019;8:59. DOI: 10.4103/abr.abr_42_19Novick DM, Swartz HA. Evidence-Based Psychotherapies for Bipolar Disorder. Focus (Am Psychiatr Publ). 2019;17(3):238-248. DOI: 10.1176/appi.focus.20190004Novick DM, Swartz HA. Evidence-Based Psychotherapies for Bipolar Disorder. Focus (Am Psychiatr Publ). 2019;17(3):238-248. DOI: 10.1176/appi.focus.20190004Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18(3):143-57. DOI: 10.3109/10673221003747955Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18(3):143-57. DOI: 10.3109/10673221003747955Forte A, Baldessarini RJ, Tondo L, Vázquez GH, Pompili M, Girardi P. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Aff ect Disord. 2015;178:71-8. DOI: 10.1016/j.jad.2015.02.011Forte A, Baldessarini RJ, Tondo L, Vázquez GH, Pompili M, Girardi P. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Aff ect Disord. 2015;178:71-8. DOI: 10.1016/j.jad.2015.02.011Rowland TA, Marwaha S. Epidemiology and risk factors for bipolar disorder. Ther Adv Psychopharmacol. 2018;8(9):251-269. DOI: 10.1177/2045125318769235Rowland TA, Marwaha S. Epidemiology and risk factors for bipolar disorder. Ther Adv Psychopharmacol. 2018;8(9):251-269. DOI: 10.1177/2045125318769235Dome P, Rihmer Z, Gonda X. Suicide Risk in Bipolar Disorder: A Brief Review. Medicina (Kaunas). 2019;55(8):403. DOI: 10.3390/medicina55080403Dome P, Rihmer Z, Gonda X. Suicide Risk in Bipolar Disorder: A Brief Review. Medicina (Kaunas). 2019;55(8):403. DOI: 10.3390/medicina55080403Liu B, Zhang Y, Fang H, Liu J, Liu T, Li L. Effi cacy and safety of long-term antidepressant treatment for bipolar disorders – A meta-analysis of randomized controlled trials. J Aff ect Disord. 2017;223:41-48. DOI: 10.1016/j.jad.2017.07.023Liu B, Zhang Y, Fang H, Liu J, Liu T, Li L. Effi cacy and safety of long-term antidepressant treatment for bipolar disorders – A meta-analysis of randomized controlled trials. J Aff ect Disord. 2017;223:41-48. DOI: 10.1016/j.jad.2017.07.023Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561-1572. DOI: 10.1016/S0140-6736(15)00241-XGrande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561-1572. DOI: 10.1016/S0140-6736(15)00241-XYatham LN. Diagnosis and management of patients with bipolar II disorder. J Clin Psychiatry. 2005;66 Suppl 1:13-7.PMID: 15693747.Yatham LN. Diagnosis and management of patients with bipolar II disorder. J Clin Psychiatry. 2005;66 Suppl 1:13-7.PMID: 15693747.Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, et al. Pharmacological profi le of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171-81. DOI: 10.1124/jpet.110.167346Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, et al. Pharmacological profi le of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171-81. DOI: 10.1124/jpet.110.167346Ishigooka J, Kato T, Miyajima M, Watabe K, Masuda T, et al. Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study. J Aff ect Disord. 2021;281:160-167. DOI: 10.1016/j.jad.2020.12.005Ishigooka J, Kato T, Miyajima M, Watabe K, Masuda T, et al. Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study. J Aff ect Disord. 2021;281:160-167. DOI: 10.1016/j.jad.2020.12.005Raison CL, Siu C, Pikalov A, Tocco M., Loebel A. C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebocontrolled trial. Brain Behav Immun. 2020;84:269-274. DOI: 10.1016/j.bbi.2019.12.010Raison CL, Siu C, Pikalov A, Tocco M., Loebel A. C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebocontrolled trial. Brain Behav Immun. 2020;84:269-274. DOI: 10.1016/j.bbi.2019.12.010Duric V, Banasr M, Franklin T, Lepack A, Adham N, et al. Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor- Dependent Antidepressant Eff ects in the Chronic Stress Model. Int J Neuropsychopharmacol. 2017;20(10):788-796. DOI: 10.1093/ijnp/pyx038Duric V, Banasr M, Franklin T, Lepack A, Adham N, et al. Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor- Dependent Antidepressant Eff ects in the Chronic Stress Model. Int J Neuropsychopharmacol. 2017;20(10):788-796. DOI: 10.1093/ijnp/pyx038Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N. Eff ects of cariprazine, a novel antipsychotic, on cognitive defi cit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol. 2016;26(1):3-14. DOI: 10.1016/j.euroneuro.2015.11.016Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N. Eff ects of cariprazine, a novel antipsychotic, on cognitive defi cit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol. 2016;26(1):3-14. DOI: 10.1016/j.euroneuro.2015.11.016Watson DJG, King MV, Gyertyán I, Kiss B, Adham N, Fone KCF. Th e dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. Eur Neuropsychopharmacol. 2016;26(2):208-224. DOI: 10.1016/j.euroneuro.2015.12.020Watson DJG, King MV, Gyertyán I, Kiss B, Adham N, Fone KCF. Th e dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. Eur Neuropsychopharmacol. 2016;26(2):208-224. DOI: 10.1016/j.euroneuro.2015.12.020Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, et al. An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Effi cacy of Cariprazine in Patients With Bipolar I Depression. Am J Psychiatry. 2016;173(3):271-81. DOI: 10.1176/appi.ajp.2015.15020164Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, et al. An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Effi cacy of Cariprazine in Patients With Bipolar I Depression. Am J Psychiatry. 2016;173(3):271-81. DOI: 10.1176/appi.ajp.2015.15020164Earley W, Burgess MV, Rekeda L, Dickinson R, Szatmári B, et al. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. Am J Psychiatry. 2019;176(6):439-448. DOI: 10.1176/appi.ajp.2018.18070824Earley W, Burgess MV, Rekeda L, Dickinson R, Szatmári B, et al. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. Am J Psychiatry. 2019;176(6):439-448. DOI: 10.1176/appi.ajp.2018.18070824Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1-56. PMID: 15000267.Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1-56. PMID: 15000267.Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, et al. Effi cacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study. BMC Psychiatry. 2013;13:138. DOI: 10.1186/1471-244X-13-138Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, et al. Effi cacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study. BMC Psychiatry. 2013;13:138. DOI: 10.1186/1471-244X-13-138Pan PY, Lee MS, Lo MC, Yang EL, Yeh CB. Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study. BMC Psychiatry. 2014;14:145. DOI: 10.1186/1471-244X-14-145Pan PY, Lee MS, Lo MC, Yang EL, Yeh CB. Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study. BMC Psychiatry. 2014;14:145. DOI: 10.1186/1471-244X-14-145Sanford M, Keating GM. Quetiapine: A review of its use in the management of bipolar depression. CNS Drugs. 2012;26(5):435-60. doi: 10.2165/11203840-000000000-00000Sanford M, Keating GM. Quetiapine: A review of its use in the management of bipolar depression. CNS Drugs. 2012;26(5):435-60. doi: 10.2165/11203840-000000000-00000Kishi T, Ikuta T, Matsuda Y, Iwata N. Quetiapine extendedrelease vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis. Neuropsychopharmacol Rep. 2019;39(3):256-259. DOI: 10.1002/npr2.12070Kishi T, Ikuta T, Matsuda Y, Iwata N. Quetiapine extendedrelease vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis. Neuropsychopharmacol Rep. 2019;39(3):256-259. DOI: 10.1002/npr2.12070Simon J, Geddes JR, Gardiner A, Rendell J, Goodwin GM, Mayer S. Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL). Bipolar Disord. 2018;20(8):733-745. DOI: 10.1111/bdi.12713Simon J, Geddes JR, Gardiner A, Rendell J, Goodwin GM, Mayer S. Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL). Bipolar Disord. 2018;20(8):733-745. DOI: 10.1111/bdi.12713Lindström L, Lindström E, Nilsson M, Höistad M. Maintenance therapy with second generation antipsychotics for bipolar disorder – A systematic review and metaanalysis. J Aff ect Disord. 2017;213:138-150. DOI: 10.1016/j.jad.2017.02.012Lindström L, Lindström E, Nilsson M, Höistad M. Maintenance therapy with second generation antipsychotics for bipolar disorder – A systematic review and metaanalysis. J Aff ect Disord. 2017;213:138-150. DOI: 10.1016/j.jad.2017.02.012Valdes M, Bertolin S, Qian H, Wong H, Lam RW, Yatham LN. Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. J Aff ect Disord. 2019;246:861-866. DOI: 10.1016/j.jad.2019.01.003Valdes M, Bertolin S, Qian H, Wong H, Lam RW, Yatham LN. Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. J Aff ect Disord. 2019;246:861-866. DOI: 10.1016/j.jad.2019.01.003Masi G, Milone A, Stawinoga A, Veltri S, Pisano S. Effi cacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder. J Clin Psychopharmacol. 2015;35(5):587-90. DOI: 10.1097/JCP.0000000000000371Masi G, Milone A, Stawinoga A, Veltri S, Pisano S. Effi cacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder. J Clin Psychopharmacol. 2015;35(5):587-90. DOI: 10.1097/JCP.0000000000000371Bahji A, Ermacora D, Stephenson C, Hawken ER, Vazquez G. Comparative effi cacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis. J Aff ect Disord. 2020;269:154-184. DOI: 10.1016/j.jad.2020.03.030Bahji A, Ermacora D, Stephenson C, Hawken ER, Vazquez G. Comparative effi cacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis. J Aff ect Disord. 2020;269:154-184. DOI: 10.1016/j.jad.2020.03.030Li DJ, Tseng PT, Stubbs B, Chu CS, Chang HY, et al. Effi cacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79(Pt B):289-301. DOI: 10.1016/j.pnpbp.2017.06.023Li DJ, Tseng PT, Stubbs B, Chu CS, Chang HY, et al. Effi cacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79(Pt B):289-301. DOI: 10.1016/j.pnpbp.2017.06.023

The authors declare that there are no conflicts of interest present.